OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+9.36%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$377M
AUM Growth
+$377M
(-26%)
Cap. Flow
-$79.5M
Cap. Flow
% of AUM
-21.07%
Top 10 Holdings %
Top 10 Hldgs %
59.98%
Holding
57
New
10
Increased
13
Reduced
12
Closed
14
Top Buys
| 1 |
Protara Therapeutics
TARA
|
$47.7M |
| 2 |
Eton Pharmaceutcials
ETON
|
$8.9M |
| 3 |
KALA BIO
KALA
|
$7.23M |
| 4 |
MTEM
Molecular Templates, Inc.
MTEM
|
$7.09M |
| 5 |
MYOV
Myovant Sciences Ltd.
MYOV
|
$4.95M |
Top Sells
Sector Composition
| 1 | Healthcare | 87.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Protara Therapeutics
TARA
$120M
| $52.1M | 13.82% | 2,208,472 +2,020,328 | +1,074% | +$47.7M |
|
|
FTSV
2
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $36.8M | 9.75% | 385,500 -176,500 | -31% | -$16.8M |
|
3
Ocular Therapeutix
OCUL
$2.12B
| $25.4M | 6.72% | 5,122,500 +15,000 | +0.3% | +$74.2K |
|
|
APTO
4
DELISTED
Aptose Biosciences, Inc.
APTO
| $23.9M | 6.33% | 4,022,000 -63,000 | -2% | -$374K |
|
5
Neurogene
NGNE
$264M
| $15.9M | 4.22% | 1,400,000 +18,700 | +1% | +$213K |
|
6
Codexis
CDXS
$246M
| $15.6M | 4.14% | 1,400,000 | – | – |
|
|
EIDX
7
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $15.5M | 4.1% | 315,550 | – | – |
|
|
8
Eton Pharmaceutcials
ETON
$464M
| $14.9M | 3.95% | 3,640,000 +2,170,544 | +148% | +$8.9M |
|
|
CCXI
9
DELISTED
ChemoCentryx, Inc.
CCXI
| $14.5M | 3.85% | 361,600 | – | – |
|
10
Stereotaxis
STXS
$261M
| $11.7M | 3.09% | 3,861,500 -251,000 | -6% | -$758K |
|
11
uniQure
QURE
$896M
| $9.97M | 2.64% | 210,000 | – | – |
|
|
ODT
12
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $9.94M | 2.63% | 360,000 +5,000 | +1% | +$138K |
|
13
Harrow
HROW
$1.44B
| $9.55M | 2.53% | 2,500,000 +160,000 | +7% | +$611K |
|
|
ATXI
14
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
| $9.25M | 2.45% | 1,035,000 | – | – |
|
|
DCPH
15
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $9.14M | 2.42% | 222,000 -2,500 | -1% | -$103K |
|
16
Xoma
XOMA
$392M
| $7.88M | 2.09% | 387,000 +13,550 | +4% | +$276K |
|
|
17
KALA BIO
KALA
$78.8M
| $7.23M | 1.92% | +782,000 | New | +$7.23M |
|
|
MTEM
18
DELISTED
Molecular Templates, Inc.
MTEM
| $7.09M | 1.88% | +533,400 | New | +$7.09M |
|
19
Avalo Therapeutics
AVTX
$122M
| $5.46M | 1.45% | 2,203,100 +12,426 | +0.6% | +$30.8K |
|
20
Crinetics Pharmaceuticals
CRNX
$2.92B
| $5.42M | 1.44% | 368,750 +102,650 | +39% | +$1.51M |
|
21
FibroGen
FGEN
$47.8M
| $5.07M | 1.34% | 146,000 | – | – |
|
|
EDAP
22
EDAP TMS
EDAP
$84.5M
| $4.98M | 1.32% | 2,193,500 +408,500 | +23% | +$927K |
|
|
MYOV
23
DELISTED
Myovant Sciences Ltd.
MYOV
| $4.95M | 1.31% | +656,000 | New | +$4.95M |
|
24
TG Therapeutics
TGTX
$4.65B
| $4.85M | 1.29% | 493,000 -86,651 | -15% | -$853K |
|
|
KDMN
25
DELISTED
Kadmon Holdings, Inc.
KDMN
| $4.83M | 1.28% | 1,152,250 +211,877 | +23% | +$888K |
|